Tagged with

China Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and no initial products, OcuMension now leads in China’s ophthalmology drug development, maintains rapid growth, and is preparing for global reach.…

USA Having terminated dozens of HIV-related research grants, the Trump administration’s assault on the field continues. In a major blow to the decades-long search for a vaccine, the US federal government has pulled the plug on the HIV vaccine programme run by the US National Institute of Health (NIH) –the world’s…

Denmark As Denmark launches its ambitious Life Science Strategy 2030, the Danish Medicines Agency (DKMA), long held as the embodiment of European regulatory excellence, is fine-tuning its priorities. New director Nils Falk Bjerregaard sees the DKMA’s role as a “facilitator of innovation,” supporting early-stage development and leveraging real-world data at home,…

Switzerland Matthew Brabazon, General Manager of EMEA at SFI Health, a global natural healthcare company, discusses the company’s shift towards branded products and its focus on clinically supported products in the areas of cognition and the microbiome sector. What sets us apart is simple: our products are clinically substantiated. We walk…

Germany A summary of some of the top stories coming out of Germany’s biopharma industry, including Bayer’s EMA win for its Eylea eye therapy; the oncology deal Merck KGaA has cut with SpringWorks Therapeutics; the bispecific antibody alliance between BMS and BioNTech, and Sartorius’ acquisition of microtissue firm MatTek.   Bayer…

Global Writing in ISPOR’s Value and Outcomes Spotlight magazine, Beth Fand Incollingo looks at why health economics and outcomes research may hold the key to solving some of healthcare’s most entrenched access and affordability issues.   Healthcare can only be widely effective if most patients can access and afford it. Yet,…

China Building a biotech from the ground up is rarely the next step for someone who has led multinational pharmaceutical giants. Yet that was the challenge Pony Lu accepted when he took the helm at VISEN Pharmaceuticals. Tasked with shaping the company from its inception, he brought not only decades of…

China 2024 marks a moment of inflection for Harbour BioMed, as the company collect the rewards of a strong global execution. In this interview, Dr Jingsong Wang reflects on the strategic, scientific, and operational advances shaping the company’s trajectory. With its proprietary HCAb platform at the core, Harbour BioMed is extending…

Global We are living in uncertain times. The US government’s rapid-fire retreat from development aid and multilateral participation has shaken up the global system but – as Brendan Shaw argues, reflecting on the 2025 World Health Assembly – this has created a major opportunity to reshape the international order for the…

USA Manuel Guzman, President of CAS, a division of the American Chemical Society, outlines the organization’s vital role in scientific knowledge management and its commitment to accelerating breakthroughs in biomedical research. In this interview, Guzman delves into CAS’s strategic partnership with Cleveland Clinic, the impact of AI and quantum computing in…

Singapore Charles Stacey, President and CEO of Cerecin, discusses the company’s strategic direction and partnerships as it advances its Alzheimer’s treatment into Phase 3 trials. He highlights the importance of collaboration with global contract research organizations and large vendors during the clinical development phase. Stacey also shares insights into Cerecin’s approach…

Switzerland With the pharmaceutical landscape growing increasingly complex, few mid-sized players manage to carve out a distinct, resilient path. Rivopharm, a Swiss-headquartered generics manufacturer, is doing just that, expanding its direct presence across Europe, targeting technically demanding niche products, and balancing growth with operational precision. In this interview, CEO Piero Poli…